241 related articles for article (PubMed ID: 12679759)
1. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy.
Serebruany VL; Malinin AI; Callahan KP; Binbrek A; Van De Werf F; Alexander JH; Granger CB; Gurbel PA;
Am Heart J; 2003 Apr; 145(4):636-42. PubMed ID: 12679759
[TBL] [Abstract][Full Text] [Related]
2. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
[TBL] [Abstract][Full Text] [Related]
3. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.
Gurbel PA; Serebruany VL; Shustov AR; Bahr RD; Carpo C; Ohman EM; Topol EJ
J Am Coll Cardiol; 1998 Jun; 31(7):1466-73. PubMed ID: 9626821
[TBL] [Abstract][Full Text] [Related]
4. Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction.
Al-Shwafi KA; de Meester A; Pirenne B; Col JJ
Am Heart J; 2003 Feb; 145(2):217-25. PubMed ID: 12595837
[TBL] [Abstract][Full Text] [Related]
5. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E
Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780
[TBL] [Abstract][Full Text] [Related]
6. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.
Van de Werf F; Cannon CP; Luyten A; Houbracken K; McCabe CH; Berioli S; Bluhmki E; Sarelin H; Wang-Clow F; Fox NL; Braunwald E
Am Heart J; 1999 May; 137(5):786-91. PubMed ID: 10220625
[TBL] [Abstract][Full Text] [Related]
7. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
Dunn CJ; Goa KL
Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052
[TBL] [Abstract][Full Text] [Related]
8. The platelet-related effects of tenecteplase versus alteplase versus reteplase.
Gurbel PA; Hayes K; Bliden KP; Yoho J; Tantry US
Blood Coagul Fibrinolysis; 2005 Jan; 16(1):1-7. PubMed ID: 15650539
[TBL] [Abstract][Full Text] [Related]
9. Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
Serebruany VL; Gurbel PA; Shustov AR; Dalesandro MR; Gumbs CI; Grabletz LB; Bahr RD; Ohman EM; Topol EJ
Stroke; 1998 Jan; 29(1):235-8. PubMed ID: 9445356
[TBL] [Abstract][Full Text] [Related]
10. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
Zhang L; Zhang ZG; Zhang C; Zhang RL; Chopp M
Stroke; 2004 Dec; 35(12):2890-5. PubMed ID: 15514182
[TBL] [Abstract][Full Text] [Related]
11. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
Van de Werf F; Barron HV; Armstrong PW; Granger CB; Berioli S; Barbash G; Pehrsson K; Verheugt FW; Meyer J; Betriu A; Califf RM; Li X; Fox NL;
Eur Heart J; 2001 Dec; 22(24):2253-61. PubMed ID: 11728145
[TBL] [Abstract][Full Text] [Related]
12. Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction.
Huisse MG; Ajzenberg N; Feldman L; Guillin MC; Steg PG
Thromb Haemost; 2009 Apr; 101(4):734-40. PubMed ID: 19350119
[TBL] [Abstract][Full Text] [Related]
13. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.
Cannon CP; McCabe CH; Gibson CM; Ghali M; Sequeira RF; McKendall GR; Breed J; Modi NB; Fox NL; Tracy RP; Love TW; Braunwald E
Circulation; 1997 Jan; 95(2):351-6. PubMed ID: 9008448
[TBL] [Abstract][Full Text] [Related]
14. ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction.
Armstrong PW; Wagner G; Goodman SG; Van de Werf F; Granger C; Wallentin L; Fu Y;
Eur Heart J; 2003 Aug; 24(16):1515-22. PubMed ID: 12919776
[TBL] [Abstract][Full Text] [Related]
15. Platelet function and fibrinolytic agents: two sides of a coin?
Callahan KP; Malinin AI; Gurbel PA; Alexander JH; Granger CB; Serebruany VL
Cardiology; 2001; 95(2):55-60. PubMed ID: 11423707
[TBL] [Abstract][Full Text] [Related]
16. Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase.
Pönitz V; Pritchard D; Grundt H; Nilsen DW
J Thromb Thrombolysis; 2006 Dec; 22(3):199-203. PubMed ID: 17111198
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
Sarullo FM; Pasquale PD; D'Alfonso G; Amerigo L; Cannizzaro S; Castello A
Ital Heart J; 2001 Aug; 2(8):605-11. PubMed ID: 11577835
[TBL] [Abstract][Full Text] [Related]
18. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.
Benedict CR; Refino CJ; Keyt BA; Pakala R; Paoni NF; Thomas GR; Bennett WF
Circulation; 1995 Nov; 92(10):3032-40. PubMed ID: 7586274
[TBL] [Abstract][Full Text] [Related]
19. Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA).
Gibson CM; Marble SJ
Clin Cardiol; 2001 Sep; 24(9):577-84. PubMed ID: 11558838
[TBL] [Abstract][Full Text] [Related]
20. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator.
Wang-Clow F; Fox NL; Cannon CP; Gibson CM; Berioli S; Bluhmki E; Danays T; Braunwald E; Van De Werf F; Stump DC
Am Heart J; 2001 Jan; 141(1):33-40. PubMed ID: 11136484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
